Eli Lilly to test cancer drugs with Merck's Keytruda and BMS's Opdivo; Portola Pharmaceuticals kicks off PhIV study aimed at FDA approval;

@FiercePharma: ICYMI: Is once-skeptical J&J coming around on pharma's breakup craze? More | Follow @FiercePharma

@CarlyHFierce: Merck CEO Frazier credits Keytruda success to slim-down strategy. Article | Follow @CarlyHFierce

> Eli Lilly ($LLY) inked two separate deals with Merck ($MRK) and Bristol-Myers Squibb ($BMY) to test its approved and experimental cancer treatments in combination with Merck's Keytruda and BMS's Opdivo. Story

> Portola Pharmaceuticals ($PTLA) launched a Phase IV study aimed at FDA approval for its adexanet alfa Factor Xa inhibitor antidote. More

> The FDA created a new department, the Office of Pharmaceutical Quality, to monitor drug quality control at pharmaceutical manufacturing facilities. Story

> U.S. regulators are taking a hard look at extended-release drugs from companies such as Teva Pharmaceutical Industries ($TEVA) and Wockhardt ($WPL). More

> China's Guangzhou Baiyunshan Pharmaceutical's shares surged in Hong Kong trading after the company announced plans to raise as much as 10 billion yuan ($1.6 billion) by selling shares to investors. Article

> The FDA banned a batch of Eli Lilly's Cialis pills from an plant in Australia after regulators found that they contained the active ingredient for Pfizer's ($PFE) rival erectile dysfunction drug Viagra. Story

Medical Device News

@FierceMedDev: Roche snatches up majority share in Foundation Medicine for $1B plus milestones. Report from FierceDiagnostics | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: JP Morgan: With $1.5B spent and a new president, NantHealth works to rationalize patient care. Article | Follow @StacyALawrence

> Biodesix bags $12M in Series E financing for blood-based lung cancer Dx. Story

> Roundup: Device companies announce new financing during JP Morgan confab

> Sleep apnea player Inspire Medical targets reimbursement to bolster launch. Article

Biotech News

@FierceBiotech: $ALNY and $ISIS strengthen RNAi alliance, agree to swap IP. FierceDrugDelivery article | Follow @FierceBiotech

@JohnCFierce: Last night I had to hug a wall to allow a stampede of biotech execs to surround the NY Times' Pollack. Dangerous work here at #JPM15. | Follow @JohnCFierce

> FDA steps in after a patient on Antares' 'low-T' drug breaks out in hives. Story

> Roche inks a $750M antibiotics deal as it re-embraces the field. Article

Biotech Research News

> Investigators electrify antibiotic R&D field with claims of a breakthrough. News

> Team takes a new approach to taming neuroinflammation. Article

> Amgen teams with MD Anderson on new BiTE programs for MDS. Story

> Scientists uncover new target for triple-negative breast cancer. Article

> Scripps researchers find a better way to make a nicotine vaccine. Report

Pharma Manufacturing News

> FDA upgrades Fresenius sterile plant once cited for insect infestation. Story

> AmerisourceBergen moving into vet drug distribution with $2.5B deal for MWI. News

> Group wants FDA to include Indian regulators on plant visits. More

> FDA stops import of Lilly's Cialis from Australia but Lilly says it doesn't make it there. Story

> AMRI buys more manufacturing capacity with deal for two Aptuit facilities. Article

And Finally… Aetna is planning to boost the incomes of its lowest-paid workers by as much as a third to attract promising candidates and reduce job turnover. Story (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.